DPP-4 Therapy Center

Patients on therapy may see increased reduction in HbA1c, lower BP, lower lipid values….   Dipeptidyl peptidase-4 (DPP-4) inhibitors are used for the treatment of type 2 diabetes. Sitagliptin was the first medication approved for people with type 2 diabetes who are taking insulin. There are not a lot of …

Decreased chance of hypoglycemic event and greater safety profile shown in use of this therapy… Diabetes is the main reason for renal failure in today’s population. Currently, the main treatment option for a hemodialysis diabetic patient is insulin therapy. Insulin therapy is a difficult regimen for many patients due to …

In a study, older patients taking Januvia reduced their A1c’s without an increased risk of hypoglycemia…. The mortality rate for elderly individuals with type 2 diabetes is twice that of elderly individuals without type 2 diabetes. That is why it is very important for elderly individuals with diabetes to optimize …

No significant difference in incidence of infections, cancer, renal failure, or severe hypoglycemia… In patients with type 2 diabetes and cardiovascular disease, the use of sitagliptin (Januvia, Merck), a dipeptidyl peptidase-4 (DPP-4) inhibitor used to lower HbA1c levels, is not associated with an increased risk of cardiovascular events, according to …

Updated label information recommendation is in light of completed cardiovascular-outcomes studies.

New treatment strategies have focused on both dipeptidyl peptidase (DPP)-4 inhibitors, and SGLT-2’s.

Study conducted in mice has shown that sitagliptin might offer beneficial effects in reversing cognitive impairment… Alzheimer’s disease (AD) is the most common form of dementia. Symptoms progress slowly and worsen over time resulting in interference with common daily activity. There is no known cure of AD, but the use …

David Levy, MD, FRCP Drugs acting on the incretin system (entero-insular axis) (Fig. 6.2) The incretin effect Bayliss and Starling inferred the existence of gut-derived substances affecting carbohydrate metabolism more than a century ago, but the incretin effect was not described until 1969: the observation that for a given achieved level …

A multinational team of researchers studied data from over 16,000 patients in the SAVOR-TIMI 53 trial…. Saxagliptin (Onglyza) is a commonly prescribed dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. An international team of researchers examined the effects of saxagliptin on glycemic stability and β-cell function in the …

David Levy, MD, FRCP Introduction The pharmacological management of blood glucose in type 2 diabetes remains the most contentious area of diabetes management, and although until relatively recently in the USA the only agents to treat blood glucose were insulin and sulphonylureas, this limited repertoire in no way inhibited the controversy, …